Immunomodulating effect of vitamin D3 derivatives on type-1 cellular immunity

Biomedical Research

Volumn 27, Issue 1, 2006, Pages 1-9

  Imazeki, Ikuo ^a   Matsuzaki, Junko ^a   Tsuji, Keiko ^a   Nishimura, Takashi ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

22 OXACALCITRIOL; ALLOANTIGEN; CALCITRIOL; COLECALCIFEROL; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 3; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ANIMAL CELL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; CELL CULTURE; CELL DIFFERENTIATION; CELLULAR DISTRIBUTION; CELLULAR IMMUNITY; CONTROLLED STUDY; CULTURE MEDIUM; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG MECHANISM; FEMALE; HELPER CELL; IMMUNE RESPONSE; IMMUNOMODULATION; MOUSE; MOUSE STRAIN; NONHUMAN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TH1 CELL;

ANIMALS; ANTIBODIES, MONOCLONAL; BONE MARROW CELLS; CELL CULTURE TECHNIQUES; CELLS, CULTURED; CHOLECALCIFEROL; CYTOTOXICITY TESTS, IMMUNOLOGIC; DENDRITIC CELLS; FEMALE; FLOW CYTOMETRY; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; IMMUNITY, CELLULAR; INTERLEUKIN-3; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, TRANSGENIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; T-LYMPHOCYTES, CYTOTOXIC; TH1 CELLS;

ANIMALIA;

EID: 33645031366     PISSN: 03886107     EISSN: 1880313X     Source Type: Journal    
DOI: 10.2220/biomedres.27.1     Document Type: Article

References (39)

1. Abe E, Miyaura C, Sakagami H, Takeda, M, Konnno K, Yamazaki T, Yoshiki S and Suda T (1981) Differentiation of mouse myeloid leukemia cells induced by lalpha,25-dihydroxyvitamin D3. Proc Natl Acad Sci USA 78, 4990-4994.
2. 3. J Nutr Sci Vitaminol 36, 21-31.
3. 3, is a potent modulator of in vivo immunoregulating activity without inducing hypercalcemia in mice. Endocrinology 124, 2645-2647.
4. Barker JN, Ashton RE, Marks R, Harris RI and Berth-Jones J (1999) Topical maxacalcitol for the treatment of psoriasis vulgaris: a placebo-controlled, double-blind, dose-finding study with active comparator. Br J Dermatol 141, 274-278.
5. + T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines. J Exp Med 195, 603-616.
6. Benagiano M, Azzurri A, Ciervo A, Amedei A, Tamburini C, Ferrari M, Telford JL, Baldari CT, Romagnani S, Cassone A, D'Elios MM and del Prete G (2003) T helper type 1 lymphocytes derive inflammation in human atherosclerotic lesions. Proc Natl Acad Sci USA 100, 6658-6663.
7. 3 inhibits antigen-induced T cell activation. J Immunol 133, 1748-1754.
8. 3 in combination with a short induction course of cyclosporin A. Endocrinology 139, 95-102.
9. Costa EM, Blau HM and Feldman D (1986) 1,25-Dihydroxyvitamin D3 receptors and hormonal responses in cloned human skeletal muscle cells. Endocrinology 119, 2214-2220.
10. + T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 389, 737-742.
11. Hirata M, Katsumata K, Masaki T, Koike N, Endo K, Tsunemi K, Ohkawa H, Kurokawa K and Fukagawa M (1999) 22-Oxacalcitriol ameliorates high-turnover bone and marked osteitis fibrosa in rats with slowly progressive nephritis. Kidney Int 56, 2040-2047.
12. 3 in uremic rats: A possible mechanism for less-calcemic action. Nephrology 4, 391-395.
13. Imazeki I (2003) Oxarol™, a medicine for the secondary hyperparathyroidism (°2HPT). Folia Pharmacol Jpn 121, 65-72.
14. Lew W, Bowcock AM and Krueger JG (2004) Psoriasis vulgaris: cutaneous lymphoid tissue supports T-cell activation and "Type 1" inflammatory gene expression. Trends Immunol 25, 295-305.
15. + T cells in the pathogenesis of organ-specific autoimmune diseases. Immunol Today 16, 34-38.
16. 3. Eur J Immunol 30, 498-508.
17. 3) and its metabolites. Clin Nephrol 16, 119-125.
18. Morimoto S, Yoshikawa K, Kozuka T, Kitano Y, Imanaka S, Fukuo K, Koh E and Kumahara Y (1986) An open study of vitamin D3 treatment in psoriasis vulgaris. Br J Dermatol 115, 421-429.
19. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA and Coffman RL (1986) Two types of murine heler T cell clone. I. Difinition according to profiles of lymphokine activities and secreated proteins. J Immunol 136, 2348-2357.
20. Mosmann TR and Sad S (1996) The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 17, 138-146.
21. Motomiya Y, Miyataka K and Onuki M (2002) The effect on immunocyte by 22-Oxacalcitol in the hemodialysis patients with hyperparathyroidism. J Jpn Soc Dial Ther 35, 1189-1192.
22. 3 analogues. Chem Pharm Bull (Tokyo) 34, 4410-4413.
23. Nashold FE, K. Hoag A, Goverman J and Hayes CE (2001) Rag-1-dependent cells are necessary for 1,25-dihydroxyvitamin D3 prevention of experimental autoimmune encephalomyelitis. J Neuroimmunol 119, 16-29.
24. Nishimura T, Brakoff SJ and Herrmann SH (1989) Inhibition of lymphokine-activetaed killer cell-mediated cytotoxicity by phorbol ester. J Immunol 142, 2155-2161.
25. Nishimura T and Ohta A (1999) A critical role for antigen-specific Th1 cells in acute liver injury in mice. J Immunol 162, 6503-6509.
26. Nishimura T, Sadata A, Yahagi C, Santa K, Otsuki K, Watanabe K, Yahata T and Habu S (1996) The therapeutic effect of interleukin-12 or its antagonist in transplantation immunity. Ann N Y Acad Sci 795, 371-374.
27. -T cells in non-MHC gene-controlled predisposition toward skewing into T helper type-2 immunity in BALB/c imminity in BALB/c mice. J Immunol 158, 5698-5706.
28. Ochi H, Wu X-M, Osoegawa M, Horiuchi I, Minohara M, Murai H, Ohyagi Y, Furiya H and Kira J (2001) Tc1/Tc2 and Th1/Th2 balance in Asian and Western types of multiple sclerosis, HTLV-associated myelopathy/tropical spastic paraparesis and hyperIgEaemic myelitis. J Neuroimmunol 119, 297-305.
29. Ohta A, Sekimoto M, Sato M, Koda T, Nishimura S, Iwakura Y, Sekikawa K and Nishimura T (2000) Indispensable role for TNF-α and IFN-γ at the effector phase of liver injury mediated by Th1 cells specific to hepatitis B virus surface antigen, J Immunol 165, 956-961.
30. 3. Specific inhibition at the level of messenger RNA. J Clin Invest 79, 1659-1664.
31. + regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 182, 18-32.
32. Sato K, Yamashita N, Yamashita N, Baba M and Matsuyama T (2003) Regulatory dendritic cells protect mice from murine acute graft-versus-host disease and leukemia relapse. Immunity 18, 367-379.
33. Sato M, Iwakabe K, Ohta A, Sekimoto M, Nakui M, Koda T, Kimura S and Nishimura T (2000) Functional heterogeneity among bone marrow-derived dendritic cells conditioned by Th1- and Th2-biasing cytokines for the generation of allogeneic cytotoxic T lymphocytes. Int Immunol 12, 335-342.
34. Simpson RU, Thomas GA and Arnold AJ (1985) identification of 1,25-dihydroxyvitamin D3 receptors and activities in muscle. J Biol Chem 260, 8882-8891.
35. Takaoka A, Tanaka Y, Tsuji T, Jinushi T, Hoshino A, Asakura Y, Mita Y, Watanabe K, Nakaie S, Togashi Y, Koda T, Matsushima K and Nishimura T (2001) A critical role for mouse CXC chemokine(s) in pulmonary neutrophilia during Th type 1-dependent airway inflammation. J Immunol 167, 2349-2353.
36. Tanaka J, Imamura M, Kasai M, Kobayashi S, Noto S, Higa T, Sakurada K and Asaka M (1997) The important balance between cytokines derived from type 1 and type 2 helper T cells in the control of graft-versus-host disease. Bone Marrow Transplant 19, 571-576.
37. Tsukamoto Y, Hanaoka M, Matsuo T, Saruta T, Nomura M and Takahashi Y (2000) Effect of 22-oxacalcitriol on bone histology of hemodialyzed patients with severe secondary hyperparathyroidism. Am J Kidney Dis 35, 458-464.
38. Wittke A, Weaver V, Mahon DB, August A and Cantorna TM (2004) Vitamin D receptor-deficient mice fail to develop experimental allergic asthma. J Immunol 173, 3432-3436.
39. Yoshizawa T, Handa Y, Uematsu Y, Takeda S, Sekine K, Yoshihara Y, Kawakami T, Arioka K, Sato H, Uchiyama Y, Msushige S, Fukamizu A, Matsumoto T and Kato S (1997) Mice lacking the vitamin D receptor exhibit impaired bone formation, uterine hypoplasia and growth retardation after weaning. Nat Genet 16, 391-396.